Skip to main content
. Author manuscript; available in PMC: 2016 Jul 12.
Published in final edited form as: Cancer Cell. 2015 Nov 9;28(5):653–665. doi: 10.1016/j.ccell.2015.10.002

Figure 6. CB-5083 demonstrates greater activity than proteasome inhibitors in solid tumor models.

Figure 6

(A) Relative levels of poly-ubiquitin measured in HCT116 or A549 xenografts in mice administered CB-5083 or proteasome inhibitors (n=3 per time point).

(B) Relative levels of CHOP measured in HCT116 xenografts in (A).

(C) Tumor growth was measured with dosing of CB-5083 or proteasome inhibitors in HCT116 (n=8-12) and A549 (n=10-12) xenograft models.

Error bars are +/− SEM. See also Figure S6.